# NEPAFOX (NCT02172976)

> Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

No report yet. It can be ordered.

- Drugs tested: FOLFIRINOX
- Indication: resectable pancreatic cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02172976
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Krankenhaus Nordwest
- Conditions: Resectable Prancreas Carcinoma
- Interventions: Gemcitabine; Oxaliplatin; 5-Fluorouracil; Irinotecan; Natriumfolinate
- Enrollment: 40
- Primary outcome: median overall survival

## Indexed commentary on NEPAFOX so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nepafox-nct02172976